Antoine Boulanger Piette1, Dounia Hamoudi1, Laetitia Marcadet1, Françoise Morin1, Anteneh Argaw1, Leanne Ward2, Jérôme Frenette3,4. 1. Centre Hospitalier Universitaire de Québec, Centre de Recherche du Centre Hospitalier de l'Université Laval (CHUQ-CHUL), Axe Neurosciences, Université Laval, Quebec City, QC, G1V 4G2, Canada. 2. Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, ON, K1H 8L1, Canada. 3. Centre Hospitalier Universitaire de Québec, Centre de Recherche du Centre Hospitalier de l'Université Laval (CHUQ-CHUL), Axe Neurosciences, Université Laval, Quebec City, QC, G1V 4G2, Canada. jerome.frenette@crchudequebec.ulaval.ca. 4. Département de Réadaptation, Faculté de Médecine, Université Laval, Quebec City, QC, G1V 0A6, Canada. jerome.frenette@crchudequebec.ulaval.ca.
Abstract
PURPOSE OF REVIEW: In Duchenne muscular dystrophy (DMD), the progressive skeletal and cardiac muscle dysfunction and degeneration is accompanied by low bone mineral density and bone fragility. Glucocorticoids, which remain the standard of care for patients with DMD, increase the risk of developing osteoporosis. The scope of this review emphasizes the mutual cohesion and common signaling pathways between bone and skeletal muscle in DMD. RECENT FINDINGS: The muscle-bone interactions involve bone-derived osteokines, muscle-derived myokines, and dual-origin cytokines that trigger common signaling pathways leading to fibrosis, inflammation, or protein synthesis/degradation. In particular, the triad RANK/RANKL/OPG including receptor activator of NF-kB (RANK), its ligand (RANKL), along with osteoprotegerin (OPG), regulates bone matrix modeling and remodeling pathways and contributes to muscle pathophysiology in DMD. This review discusses the importance of the muscle-bone unit in DMD and covers recent research aimed at determining the muscle-bone interactions that may eventually lead to the development of multifunctional and effective drugs for treating muscle and bone disorders regardless of the underlying genetic mutations in DMD.
PURPOSE OF REVIEW: In Duchenne muscular dystrophy (DMD), the progressive skeletal and cardiac muscle dysfunction and degeneration is accompanied by low bone mineral density and bone fragility. Glucocorticoids, which remain the standard of care for patients with DMD, increase the risk of developing osteoporosis. The scope of this review emphasizes the mutual cohesion and common signaling pathways between bone and skeletal muscle in DMD. RECENT FINDINGS: The muscle-bone interactions involve bone-derived osteokines, muscle-derived myokines, and dual-origin cytokines that trigger common signaling pathways leading to fibrosis, inflammation, or protein synthesis/degradation. In particular, the triad RANK/RANKL/OPG including receptor activator of NF-kB (RANK), its ligand (RANKL), along with osteoprotegerin (OPG), regulates bone matrix modeling and remodeling pathways and contributes to muscle pathophysiology in DMD. This review discusses the importance of the muscle-bone unit in DMD and covers recent research aimed at determining the muscle-bone interactions that may eventually lead to the development of multifunctional and effective drugs for treating muscle and bone disorders regardless of the underlying genetic mutations in DMD.
Authors: Susan A Novotny; Gordon L Warren; Angela S Lin; Robert E Guldberg; Kristen A Baltgalvis; Dawn A Lowe Journal: Neuromuscul Disord Date: 2011-01-21 Impact factor: 4.296
Authors: Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin Journal: Lancet Neurol Date: 2009-11-27 Impact factor: 44.182
Authors: Sébastien S Dufresne; Nicolas A Dumont; Antoine Boulanger-Piette; Val A Fajardo; Daniel Gamu; Sandrine-Aurélie Kake-Guena; Rares Ovidiu David; Patrice Bouchard; Éliane Lavergne; Josef M Penninger; Paul C Pape; A Russell Tupling; Jérôme Frenette Journal: Am J Physiol Cell Physiol Date: 2016-01-28 Impact factor: 4.249
Authors: David W Hammers; Margaret M Sleeper; Sean C Forbes; Ai Shima; Glenn A Walter; H Lee Sweeney Journal: J Am Heart Assoc Date: 2016-08-09 Impact factor: 5.501
Authors: Pojchong Chotiyarnwong; Eugene McCloskey; Richard Eastell; Michael R McClung; Evelien Gielen; John Gostage; Michele McDermott; Arkadi Chines; Shuang Huang; Steven R Cummings Journal: J Bone Miner Res Date: 2020-04-02 Impact factor: 6.390